Skip to main content
Top

Journal of Endocrinological Investigation

Issue 9/2003

Content (20 Articles)

Effects of GH and insulin-like growth factor-I on body composition

J. Svensson, L. Lönn, G. Johannsson, B.Å. Bengtsson

Erythropoietin

W. Jelkmann

Exercise, hormones, and body temperature. Regulation and action of GH during exercise

J. O. L. Jørgensen, M. Krag, J. Kanaley, J. Møller, T. K. Hansen, N. Møller, J. S. Christiansen, H. Ørskov

Neuroendocrine control of GH release during acute aerobic exercise

A. Weltman, L. Wideman, J. Y. Weltman, J. D. Veldhuis

Metabolic response to exercise

P. De Feo, C. Di Loreto, P. Lucidi, G. Murdolo, N. Parlanti, A. De Cicco, F. Piccioni F Santeusanio

Ageing, growth hormone and physical performance

F. Lanfranco, L. Gianotti, R. Giordano, M. Pellegrino, M. Maccario, E. Arvat

Exercise-induced endocrine pathologies

M. P. Warren, L. R. Goodman

Mechanisms underlying the neuroendocrine response to physical exercise

A. Leal-Cerro, A. Gippini, M. J. Amaya, M. Lage, J. A. Mato, C. Dieguez, F. F. Casanueva

Indirect evidence of hormone abuse. Proof of doping?

F. Minuto, A. Barreca, G. Melioli

Problems with GH doping in sports

M. Bidlingmaier, Z. Wu, C. J. Strasburger

Diabetes and exercise

F. Santeusanio, C. Di Loreto, P. Lucidi, G. Murdolo, A. De Cicco, N. Parlanti, F. Piccioni, P. De Feo

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine